Single-cell RNA-Seq reveals the potential risk of anti-mesothelin CAR T Cell therapy toxicity to different organs in humans
暂无分享,去创建一个
F. Tong | Rui-guang Zhang | Xiaorong Dong | Q. Qian | Zhicai Lin | Zhong Li | Yan Sun | Ling Peng | Lu Wen | Yu Huang | Kaiping Zhao | Yuanyuan Chen | X. Dong | Xiaorong Dong
[1] Qian Zhang,et al. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice , 2021, Molecular therapy oncolytics.
[2] S. Albelda,et al. Mesothelin-targeted CAR-T cell therapy for solid tumors , 2020, Expert opinion on biological therapy.
[3] Y. Hu,et al. CAR T-cell therapy for triple-negative breast cancer: Where we are. , 2020, Cancer letters.
[4] D. Torigian,et al. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] Peng Li,et al. Mesothelin as a biomarker for targeted therapy , 2019, Biomarker Research.
[6] Suna Wang,et al. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer , 2019, Journal of Hematology & Oncology.
[7] E. Eyras,et al. CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity , 2019, Leukemia.
[8] Lai Guan Ng,et al. Dimensionality reduction for visualizing single-cell data using UMAP , 2018, Nature Biotechnology.
[9] Liming Lu,et al. Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo , 2018, Experimental and therapeutic medicine.
[10] M. Shadman,et al. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. , 2018, Blood.
[11] D. Torigian,et al. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. , 2018, Gastroenterology.
[12] C. Halberstadt. What We Are. , 2017, JAMA.
[13] K. Curran,et al. Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.
[14] E. D. de Vries,et al. Functional Genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types , 2015, Oncotarget.
[15] Zhehai Wang,et al. Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects , 2014, Molecular Cancer.
[16] D. Torigian,et al. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.
[17] C. Sima,et al. Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma , 2013, Clinical Cancer Research.
[18] K. Konstantopoulos,et al. Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation , 2013, Scientific Reports.
[19] B. Levine,et al. T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans , 2013, Cancer Immunology Research.
[20] S. Sleijfer,et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] C. Sima,et al. Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients , 2012, Clinical Cancer Research.
[22] Q. Yao,et al. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression , 2011, Molecular Cancer.
[23] S. Rosenberg,et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[24] Shenmin Zhang,et al. HSP70 INHIBITS APOPTOSIS IN PANCREATIC CANCER CELLS BY TWO INDEPENDENT MECHANISMS: ATTENUATING CYTOSOLIC CA2+ AND STABILIZING LYSOSOMES , 2007 .